Marrow Transplantation for Chronic Myeloid Leukemia

  • Reginald A. Clift
Part of the Cancer Treatment and Research book series (CTAR, volume 76)


Chronic myeloid leukemia (CML) is a relatively common disease mainly afflicting patients older than 40 years. It was the first malignant disease shown to be associated with a change in chromosomal pattern [1,2], and the molecular biology of CML has been intensively investigated [3–6]. It is one of a group of leukemias known to arise because of a translocation that repositions part of the c-ABL proto-oncogene situated on chromosome 9 to a position adjacent to the breakpoint cluster region (BCR) on chromosome 22 [3,4]. This translocation usually produces a distinctively malformed chromosome 22 (referred to as the Ph chromosome) and always creates a length of corrupted genetic information known as the BCR-ABL rearrangement. The resulting fusion gene directs the synthesis of chimeric proteins (p210BCR-ABL or pl90BCR-ABL) with readily detectable in vitro tyrosine kinase activity [5]. It is thought that these proteins arise as a result of different breakpoint locations in the BCR region.


Chronic Myeloid Leukemia Chronic Myelogenous Leukemia Acute GVHD Accelerate Phase Nonrelapse Mortality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nowell PC, Hungerford DA: A minute chromosome in human granulocytic leukemia. Science 132:1497, 1960.Google Scholar
  2. 2.
    Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 243:290, 1973.PubMedGoogle Scholar
  3. 3.
    Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G: Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 306:239, 1983.PubMedGoogle Scholar
  4. 4.
    Groffen J, Stephenson JR, Heisterkamp N, deKlein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93, 1984.PubMedGoogle Scholar
  5. 5.
    Konopka JB, Watanabe SM, Witte ON: An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035, 1984.PubMedGoogle Scholar
  6. 6.
    Daley GQ, van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990.PubMedGoogle Scholar
  7. 7.
    Fialkow PJ, Jacobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/ macrophage. Am J Med 63:125, 1977.PubMedGoogle Scholar
  8. 8.
    Martin PJ, Najfeld V, Fialkow PJ: B-lymphoid cell involvement in chronic myelogenous leukemia: Implications for the pathogenesis of the disease. Cancer Genet Cytogenet 6:359, 1982.PubMedGoogle Scholar
  9. 9.
    Raskind WH, Ferraris AM, Najfeld V, Jacobson RJ, Moohr JW, Fialkow PJ: Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia 8:1163, 1993.Google Scholar
  10. 10.
    Kurzrock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990, 1988.PubMedGoogle Scholar
  11. 11.
    Kurzrock R, Talpaz M: The molecular pathology of chronic myelogenous leukaemia. Br J Haematol 79 (Suppl 1):34, 1991.PubMedGoogle Scholar
  12. 12.
    Dobrovic A, Peters GB, Ford JH: Molecular analysis of the Philadelphia chromosome. Chromosoma 100:479, 1991.PubMedGoogle Scholar
  13. 13.
    Clift RA, Appelbaum FR, Thomas ED: Editorial: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954, 1993.PubMedGoogle Scholar
  14. 14.
    Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, Masaoka T, McGlave PB, Messner H, O’Reilly RJ, Reiffers J, Rimm AA, Speck B, Veum-Stone JA, Wingard JR, Zwaan FE, Bortin MM: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235, 1993.PubMedGoogle Scholar
  15. 15.
    Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155, 1986.PubMedGoogle Scholar
  16. 16.
    Karanas A, Silver RT: Characteristics of the terminal phase of chronic granulocytic leukemia. Blood 32:445, 1968.PubMedGoogle Scholar
  17. 17.
    Theologides A: Unfavorable signs in patients with chronic myelocytic leukemia. Ann Intern Med 76:95, 1972.PubMedGoogle Scholar
  18. 18.
    Spiers ASD: Metamorphosis of chronic granulocytic leukaemia: Diagnosis, classification and management. Br J Haematol 41:1, 1979.PubMedGoogle Scholar
  19. 19.
    Johansson B, Mertens F, Fioretos T, Heim S, Kristoffersson U, Mandahl N, Bartram CR, Mitelman F: Remarkably long survival of a patient with Ph-positive chronic myeloid leukemia and 5′ ber rearrangement. Leukemia 4:448, 1990.PubMedGoogle Scholar
  20. 20.
    Sproul AM, Mills KI, McDonald GA, Burnett AK: Absence of bcr rearrangement and bcr/ab1 RNA in a patient with a 31 year survival of CML. Leukemia 4:450, 1990.PubMedGoogle Scholar
  21. 21.
    Minot GR, Buckman TE, Isaacs R: Chronic myelogenous leukemia. N Engl J Med 82:1489, 1924.Google Scholar
  22. 22.
    Tura S, Baccarani M, Corbelli G, The Italian Cooperative Study Group in CML: Staging of chronic myeloid leukaemia. Br J Haematol 47:105, 1981.PubMedGoogle Scholar
  23. 23.
    Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C: Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 63:789, 1984.PubMedGoogle Scholar
  24. 24.
    Keating A, Wang X, Laraya P: Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 83:1744, 1994.PubMedGoogle Scholar
  25. 25.
    Kantarjian HM, Talpaz M: Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 6:180, 1988.PubMedGoogle Scholar
  26. 26.
    McGlave P, Weisdorf D: Evaluation of potentially curative therapy for CML. J Clin Oncol 6:181, 1988.Google Scholar
  27. 27.
    Hehlmann R, Heimpel H, Kolb HJ, Heinze B, Hochhaus A, Griesshammer M, Pralle H, Queisser WP, Essers U, Falge C, et al.: The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leuk Lymphoma 11(Suppl 1):159, 1993.PubMedGoogle Scholar
  28. 28.
    Perol C, Najean Y, Tanzer J, Jacquillat C, Boiron M, Bernard J: Aplasia caused by busulfan in chronic myeloid leukemia. Nouv Rev Fr Hematol 7:884, 1967.PubMedGoogle Scholar
  29. 29.
    Olmer J, Muratori R, Gabriel B, Canu AM: Serious hematological accidents due to Myleran in the treatment of chronic myeloid leukemia. Marseille Med 105:330, 1968.PubMedGoogle Scholar
  30. 30.
    Albrecht M, Tackmann W, Pribilla W: Aplastic anemia in myleran overdose. Med Klin 66:126, 1971.PubMedGoogle Scholar
  31. 31.
    Oliner HL, Schwartz RS, Rubio F, Dameshek W: Interstitial pulmonary fibrosis following busulfan therapy. Am J Med 31:134, 1961.PubMedGoogle Scholar
  32. 32.
    Heard BE, Cooke RA: Busulphan lung. Thorax 23:187, 1968.PubMedGoogle Scholar
  33. 33.
    Kobayashi S, Ishikawa M, Wakabayashi Y, Hashimoto M, Hirose S: Busulfan lung exacerbated during steroid therapy: A review of Japanese literature. Jpn J Clin Hematol 31:1884, 1990.Google Scholar
  34. 34.
    Brittig F, Hargita M, Marton E, Kecskes L, Tehenes S: ‘Busulfan lung’ simulating tumor. Orv Hetil 134:697, 1993.PubMedGoogle Scholar
  35. 35.
    Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser WP, Loeffler H, Heinze B, Georgii A, Wussow PV, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Hochhaus A, Queisser U, Sick C, Meyer P, Schmitz M, Verpoort K, Eimermacher H, Walther F, Westerhausen M, Kleeberg UR, Heilein A, Kabisch A, Barz C, Zimmerman R, Meuret G, Tichelli A, Berdel WB, Kanz L, Anger B, Tigges FJ, Schmid L, Brockhaus W, Zankovich R, Schlafer U, Weissenfeis I, Mainzer K, Tobler A, Perker M, Hohnloser J, Messener D, Thiele J, Buhr T, Ansari H, and the German CML study group: Randomized comparison of busulfan and hydroxyurea in chronic myelo-genous leukemia: Prolongation of survival by hydroxyurea. Blood 82:398, 1993.PubMedGoogle Scholar
  36. 36.
    Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Chronic myelogenous leukemia: A concise update. Blood 82:691, 1993.PubMedGoogle Scholar
  37. 37.
    Talpaz M, McCredie KB, Mavligit GM, Gutterman JU: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62:689, 1983.PubMedGoogle Scholar
  38. 38.
    Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alphaA in chronic myelogenous leukemia. N Engl J Med 314:1065, 1986.PubMedGoogle Scholar
  39. 39.
    Egert G, Kanz L, Löhr GW, Fauser AA: Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia with interferon alpha. Blut 60:282, 1990.PubMedGoogle Scholar
  40. 40.
    Claxton D, Deisseroth A, Talpaz M, Reading C, Kantarjian H, Trujillo J, Stass SA, Gooch G, Spitzer G: Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood 79:997, 1992.PubMedGoogle Scholar
  41. 41.
    Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU: Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome positive patients. Ann Intern Med 114:522, 1991.Google Scholar
  42. 42.
    Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai KR, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD: Prolonged subcutaneous administration of recombinant a2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82:2975, 1993.PubMedGoogle Scholar
  43. 43.
    The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994.Google Scholar
  44. 44.
    Fefer A, Cheever MA, Thomas ED, Boyd C, Ramberg R, Glucksberg H, Buckner CD, Storb R: Disappearance of Ph positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med 300:333, 1979.PubMedGoogle Scholar
  45. 45.
    Fefer A, Cheever MA, Greenberg PD, Appelbaum FR, Boyd CN, Buckner CD, Kaplan HG, Ramberg R, Sanders JE, Storb R, Thomas ED: Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med 306:63, 1982.PubMedGoogle Scholar
  46. 46.
    Doney K, Buckner CD, Sale GE, Ramberg R, Boyd C, Thomas ED: Treatment of chronic granulocytic leukemia by chemotherapy, total body irradiation and allogeneic bone marrow transplantation. Exp Hematol 6:738, 1978.PubMedGoogle Scholar
  47. 47.
    Clift RA, Buckner CD, Thomas ED, Doney K, Fefer A, Neiman PE, Singer J, Sanders J, Stewart P, Sullivan KM, Deeg J, Storb R: The treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 2:621, 1982.PubMedGoogle Scholar
  48. 48.
    Goldman JM, Baughan ASJ, McCarthy DM, Worsley AM, Hows JM, Gordon-Smith EC, Catovsky D, Batchelor JR, Goolden AWG, Galton DAG: Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 2:623, 1982.PubMedGoogle Scholar
  49. 49.
    McGlave PB, Arthur DC, Kim TH, Ramsay NKC, Hurd DD, Dersey J: Successful allogeneic bone marrow transplantation for patients in the accelerated phase of chronic granulocytic leukaemia. Lancet 2:625, 1982.PubMedGoogle Scholar
  50. 50.
    Storb R, Deeg HJ, Thomas ED, Appelbaum FR, Buckner CD, Cheever MA, Clift RA, Doney KC, Flournoy N, Kennedy MS, Loughran TP, McGuffin RW, Sale GE, Sanders JE, Singer JW, Stewart PS, Sullivan KM, Witherspoon RP: Marrow transplantation for chronic myelocytic leukemia: A controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 66:698, 1985.PubMedGoogle Scholar
  51. 51.
    Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986.PubMedGoogle Scholar
  52. 52.
    Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Meyers J, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase. A randomized trial of two irradiation regimens. Blood 77:1660, 1991.PubMedGoogle Scholar
  53. 53.
    Tutschka PJ, Copelan EA, Kapoor N: Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation. Transplant Proc 21:2952, 1989.PubMedGoogle Scholar
  54. 54.
    Copelan EA, Grever MR, Kapoor N, Tutschka PJ: Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukemia in accelerated or blastic phase. Br J Haematol 71:487, 1989.PubMedGoogle Scholar
  55. 55.
    Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Concannon AJ, Avalos B, Tutschka PJ, Kapoor N, Brodsky I, Topolsky D, Bulova SI, Copelan EA: Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 80:1090, 1992.PubMedGoogle Scholar
  56. 56.
    Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994.PubMedGoogle Scholar
  57. 57.
    McDonald GB, Hinds MS, Fisher LD, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multi-organ failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255, 1993.PubMedGoogle Scholar
  58. 58.
    Essell JH, Thompson JM, Halvorson RD, Snyder MJ, Johnson RA, Rubinsak JR: Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 79:2784, 1992.PubMedGoogle Scholar
  59. 59.
    Snyder DS, Negrin RS, O’Donnell MR, Chao NJ, Amylon MD, Long GD, Nademanee AP, Stein AS, Parker PM, Smith EP, Somlo G, Margolin K, Molina A, Stepan DE, Lipsett JA, Hoppe RT, Slovak ML, Niland JC, Dagis AC, Wong RM, Forman SJ, Blume KG: Fractionated total body irradiation and high dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia. Blood 84:1672, 1994.PubMedGoogle Scholar
  60. 60.
    Sanders JE, Buckner CD, Leonard JM, Sullivan KM, Witherspoon RP, Deeg HJ, Storb R, Thomas ED: Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. Transplantation 36:252, 1983.PubMedGoogle Scholar
  61. 61.
    Deeg HJ, Flournoy N, Sullivan KM, Sheehan K, Buckner CD, Sanders JE, Storb R, Witherspoon RP, Thomas ED: Cataracts after total body irradiation and marrow transplantation: A sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys 10:957, 1984.PubMedGoogle Scholar
  62. 62.
    Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM: Competitive poly-merase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929, 1993.PubMedGoogle Scholar
  63. 63.
    Arcese W, Goldman JM, D’Arcangelo E, Schattenberg A, Nardi A, Apperley JF, Frassoni F, Aversa F, Prentice HG, Ljungman P, Ferrant A, Marosi C, Sayer H, Niederwieser D, Arnold R, Bandini G, Carreras E, Parker A, Frappaz D, Mandelli F, Gratwohl A: Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 82:3211, 1993.PubMedGoogle Scholar
  64. 64.
    Young JL, Percy CL, Asire AJ: Surveillance epidemiology and results, incidence and mortality data: 1973–1977. NCI Monogr 57:91, 1981.Google Scholar
  65. 65.
    Heim S, Mitelman F: Multistep cytogenetic scenario in chronic myeloid leukemia. In Klein G (ed): Advances in Viral Oncology. New York: Raven Press, 1987, p 53.Google Scholar
  66. 66.
    Sokal JE, Gomez GA, Baccarani M, Tura S, Clarkson BD, Cervantes F, Rozman C, Carbonell F, Anger B, Heimpel H, Nissen NI, Robertson JE: Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome positive chronic granulocytic leukemia. Blood 72:294, 1988.PubMedGoogle Scholar
  67. 67.
    Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA: Allogeneic bone marrow transplantation for chronic myelo-genous leukemia. Lancet 1:665, 1984.PubMedGoogle Scholar
  68. 68.
    Martin PJ, Clift RA, Fisher LD, Buckner CD, Hansen JA, Appelbaum FR, Doney KC, Sullivan KM, Witherspoon RP, Storb R, Thomas ED: HLA-identical marrow transplantation during accelerated phase chronic myelogenous leukemia: Analysis of survival and remission duration. Blood 72:1978, 1988.PubMedGoogle Scholar
  69. 69.
    Devergie A, Reiffers J, Vernant JP, Herve P, Guyotat D, Maraninchi D, Rio B, Michallet M, Jouet JP, Milpied N, Leblond V, Pico J, Attal M, Belanger C, Bordigoni P, Leporrier M, Ifrah N, Gratecos N, Bergerat JP, Legros M, Frappaz D, Gluckman E: Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: Factors associated with relapse. Bone Marrow Transplant 5:379, 1990.PubMedGoogle Scholar
  70. 70.
    Clift RA, Buckner CD, Thomas ED, Bryant E, Anasetti C, Bensinger WI, Bowden R, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 84:4368, 1994.PubMedGoogle Scholar
  71. 71.
    Higano CS, Raskind WH, Singer JW: Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80:1437, 1992.PubMedGoogle Scholar
  72. 72.
    Higano CS, Raskind WH, Singer JW: Use of interferon alfa-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation. Acta Haematol 89(Suppl 1): 8, 1993.PubMedGoogle Scholar
  73. 73.
    Kolb HJ, Mittermüller J, Clemm CH, Holler G, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990.PubMedGoogle Scholar
  74. 74.
    Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988.PubMedGoogle Scholar
  75. 75.
    Bortin MM, Horowitz MM, Rimm AA: Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 10:113, 1992.PubMedGoogle Scholar
  76. 76.
    Bauduer F, Delmer A, Blanc MC, Delmas-Marsalet B, Cadiou M, Rio B, Marie JP, Zittoun R: Treatment of chronic myelogenous leukemia in blast crisis in accelerated phase with high-or intermediate-dose cytosine arabinoside and ansacrine. Leuk Lymphoma 10:195, 1993.PubMedGoogle Scholar
  77. 77.
    Derderian PM, Kantarjian HM, Talpaz M, O’Brien S, Cork A, Estey E, Pierce S, Keating M: Chronic myelogenous leukemia in the lymphoid blastic stage: Characteristics, treatment response and prognosis. Am J Med 94:69, 1993.PubMedGoogle Scholar
  78. 78.
    Helenglass G, Treleaven J, Parikh P, Aboud H, Smith C, Powles R: Delayed engraftment associated with splenomegaly in patients undergoing bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 5:247, 1990.PubMedGoogle Scholar
  79. 79.
    Banaji M, Bearman SI, Buckner CD, Clift RA, Bensinger WI, Petersen FB, Slichter SJ, McGuffin RW, Sanders JE, Stewart PS, Hill RS, Deeg HJ, Storb R, Thomas ED: The effects of splenectomy on engraftment and platelet transfusion requirements in patients with chronic myelogenous leukemia undergoing marrow transplantation. Am J Hematol 22:275, 1986.PubMedGoogle Scholar
  80. 80.
    Gratwohl A, Gluckman E, Goldman J, Zwaan F: Effect of splenectomy before bone marrow transplantation on survival in chronic granulocytic leukaemia. Lancet 2:1290, 1985.PubMedGoogle Scholar
  81. 81.
    Gratwohl A, Hermans J, Biezen AV, Arcese W, De Witte T, Debusscher L, Ernst P, Ferrant A, Frassoni F, Gahrton G, Iriondo A, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schmitz N, Siegert W, Torres-Gomez A, Vernant JP, Zwaan FE: No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia: Results of a prospective randomized study. Bone Marrow Transplant 10:147, 1992.PubMedGoogle Scholar
  82. 82.
    Beatty PG, Ash R, Hows JM, McGlave PB: The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: Experience of four marrow transplant centers. Bone Marrow Transplant 4:287, 1989.PubMedGoogle Scholar
  83. 83.
    McGlave PB, Beatty P, Ash R, Hows JM: Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: Results in 102 cases. Blood 75:1728, 1990.PubMedGoogle Scholar
  84. 84.
    McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543, 1993.PubMedGoogle Scholar
  85. 85.
    Beatty PG, Anasetti C, Hansen JA, Longton GM, Sanders JE, Martin PJ, Mickelson EM, Choo SY, Petersdorf EW, Pepe MS, Appelbaum FR, Bearman SI, Buckner CD, Clift RA, Petersen FB, Singer J, Stewart PS, Storb RS, Sullivan KM, Tesler MC, Witherspoon RP, Thomas ED: Marrow transplantation from unrelated donors for treatment of hematologic malignancies: Effect of mismatching for one HLA locus. Blood 81:249, 1993.PubMedGoogle Scholar
  86. 86.
    Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T, Flomenberg N: Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 83:1980, 1994.PubMedGoogle Scholar
  87. 87.
    Mackinnon S, Hows JM, Goldman JM, Arthur CK, Hughes T, Apperley JF, Jones L, Batchelor JR, Brookes P, Catovsky D, Galton DAG, Bidwell J, Bradley B, Cleaver S, Hale G, Waldmann H: Bone marrow transplantation for chronic myeloid leukemia: The use of histocompatible unrelated volunteer donors. Exp Hematol 18:421, 1990.PubMedGoogle Scholar
  88. 88.
    Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP: Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Nati Acad Sci USA 85:5698, 1988.Google Scholar
  89. 89.
    Kohler S, Galili N, Sklar JL, Donion TA, Blume KG, Cleary ML: Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia. Leukemia 4:541, 1990.PubMedGoogle Scholar
  90. 90.
    Morgan GJ, Janssen JWG, Guo AP, Widemann CM, Hughes T, Gow J, Goldman JM, Bartram CR: Polymerase chain reaction for detection of residual leukemia. Lancet 1:928, 1989.PubMedGoogle Scholar
  91. 91.
    Cabert J, Lafage M, Maraninchi D, Thuret I, Carcassone Y, Mannoni P: Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation. Lancet 2:1125, 1989.Google Scholar
  92. 92.
    DeLage R, Soiffer RJ, Dear K, Ritz J: Clinical significance of bcr-abl rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 78:2759, 1991.PubMedGoogle Scholar
  93. 93.
    Hughes TP, Morgan GJ, Martiat P, Goldman JM: Detection of residual leukemia after bone marrow transplantation for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse. Blood 77:874, 1991.PubMedGoogle Scholar
  94. 94.
    Lee M, Khouri I, Champlin R, Kantarjian H, Talpaz M, Trujillo J, Freireich E, Deisseroth A, Stass S: Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol 82:708, 1992.PubMedGoogle Scholar
  95. 95.
    Miyamura K, Tahara T, Tanimoto M, Morishita Y, Kawashima K, Morishima Y, Saito H, Tsuzuki S, Takeyama K, Kodera Y, Matsuyama K, Hirabashi N, Yamada H, Naito K, Imai K, Sakamaki H, Asai O, Miqutani S: Long persistant bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients. Blood 81:1089, 1993.PubMedGoogle Scholar
  96. 96.
    Buckner CD, Clift RA: Timing of allogeneic marrow transplants for patients with chronic myeloid leukemia. In Champlin RE, Gale RP (eds): Advances and Controversies in Bone Marrow Transplantation — Keystone Symposia, 1994. New York: Alan R. Liss, 1994, in press.Google Scholar
  97. 97.
    Higano C, Raskind W, Flowers M: Alpha interferon (IFN) results in high complete cytogenetic response rate in patients with cytogenetic-only relapse of chronic myelogenous leukemia (CML) after marrow transplantation (BMT) (abstr). Blood 82(Suppl 1):169, 1993.Google Scholar
  98. 98.
    Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, Tuinen PV, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310, 1993.PubMedGoogle Scholar
  99. 99.
    Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 330:100, 1994.PubMedGoogle Scholar
  100. 100.
    Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79:1379, 1992.PubMedGoogle Scholar
  101. 101.
    Cullis JO, Schwarer AP, Hughes TP, Hows JM, Franklin I, Morgenstern G, Goldman JM: Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted marrow: Feasibility of using busulphan alone for reconditioning. Br J Haematol 80:33, 1992.PubMedGoogle Scholar
  102. 102.
    Thomas ED, Clift RA: Indications for marrow transplantation in chronic myelogenous leukemia. Blood 73:861, 1989.PubMedGoogle Scholar
  103. 103.
    Buckner CD, Clift RA, Fefer A, Neiman PE, Storb R, Thomas ED: Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 2:138, 1974.PubMedGoogle Scholar
  104. 104.
    Buckner CD, Stewart P, Clift RA, Fefer A, Neiman PE, Singer J, Storb R, Thomas ED: Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 6:96, 1978.PubMedGoogle Scholar
  105. 105.
    Goldman JM, Catovsky D, Hows J, Spiers ASD, Galton DAG: Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. Br Med J 1:1310, 1979.PubMedGoogle Scholar
  106. 106.
    Haines ME, Goldman JM, Worsley AM, McCarthy DM, Wyatt SE, Dowding C, Kearney L, Th'ng KH, Wareham NJ, Pollock A, Galvin MC, Samson D, Geary CG, Catovsky D, Galton DAG: Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: Probable prolongation of survival for some patients. Br J Haematol 58:711, 1984.PubMedGoogle Scholar
  107. 107.
    Reiffers J, Trouette R, Marit G, Montastruc M, Faberes C, Cony-Makhoul P, David B, Bourdeau MJ, Bilhou-Nabera C, Lacombe F, Feuillatre-Fabre F, Vezon G, Bernard PH, Broustet A: Autologous blood stem cell transplantation for chronic granulocytic leukaemia: A report of 47 cases. Br J Haematol 77:339, 1991.PubMedGoogle Scholar
  108. 108.
    Matulonis UA, Griffin JD, Canellos GP: Autologous peripheral blood stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol 45:283, 1994.PubMedGoogle Scholar
  109. 109.
    Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC: Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 308: 1493, 1983.PubMedGoogle Scholar
  110. 110.
    Barnett MJ, Eaves CJ, Phillips GL, Kalousek DK, Klingemann H-G, Lansdorp PM, Reece DE, Shepherd JD, Shaw GJ, Eaves AC: Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture. Bone Marrow Transplant 4:345, 1989.PubMedGoogle Scholar
  111. 111.
    Barnett MJ, Eaves CJ, Eaves AC: Autografting in chronic myeloid leukemia. In Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston: Blackwell, 1994, p 743.Google Scholar
  112. 112.
    Barnett MJ, Eaves CJ, Phillips GL, Hogge DE, Klingemann HG, Lansdorp PM, Nantel SH, Reece DE, Shepherd JD, Sutherland HJ, Eaves AC: Autografting in chronic myeloid leukemia with cultured marrow: Update of the Vancouver study. Stem Cells 11(Suppl 3):64, 1993.PubMedGoogle Scholar
  113. 113.
    DeFabritiis P, Sandrelli A, Meloni G, Alimena G, Montefusco E, Defazio D, Mandelli F: Persistent suppression of granulo-erythropoietic precursor cells in alpha interferon treated CML patients undergoing autologous stem cell transplantation: In vitro and clinical results. Prog Clin Biol Res 333:225, 1990.Google Scholar
  114. 114.
    Simonssen B, Oberg G, Killander A, Bjoreman M, Gahrton G, Hast R, Turesson I, Uden AM, Malm C, Vilen L, Wahlin A, Lofvenberg E, Carneskog J, Westin J: Intensive treatment in order to minimize the Ph positive clone in chronic myelogenic leukemia. Stem Cells 11(Suppl 3):73, 1993.Google Scholar
  115. 115.
    Carella AM, Podesta M, Frassoni F, Raffo MR, Pollicardo N, Pungolino E, Vimercati R, Sessarego M, Parodi C, Rabitti C, Ferrero R, Benvenuto F, Figari O, Carlier P, Levcasic G, Valbonesi M, Vitale V, Giordano D, Pierluigi D, Nati S, Guerracio A, Rosso C, Saglio G: Collection of ‘normal’ blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia (abstr). Bone Marrow Transplant 12:267, 1993.PubMedGoogle Scholar
  116. 116.
    Carella AM, Podesta M, Frassoni F, Pungolino E, Pollicardo N, Raffo MR, Ferrero R, Benvenuto F, Figari O, Giordano D, Lercari G, Carlier P, Valbonesi M, Vitale V, Parodi M, Gallamini A, Saglio G, Marmont A: Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion (abstr). Stem Cells 11(Suppl 3):67, 1993.PubMedGoogle Scholar
  117. 117.
    Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Brenner M, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reading C: Genetic marking shows that Ph + cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in CML. Blood 83:3068, 1994.PubMedGoogle Scholar
  118. 118.
    Carlo-Stella C, Mangoni L, Piovani G, Almici C, Garau D, Caramati C, Rizzoli V: In vitro purging in chronic myelogenous leukemia: Effect of mafosfamide and recombinant granulocyte macrophage colony-stimulating factor. Bone Marrow Transplant 8:265, 1991.PubMedGoogle Scholar
  119. 119.
    McGlave PB, Arthur D, Miller WJ, Lasky L, Kersey J: Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 6:115, 1990.PubMedGoogle Scholar
  120. 120.
    Becker M, Fabrega S, Belloc F, Rice A, Barbu V, Reiffers J: Interferon gamma is effective for BM purging in a patient with CML. Bone Marrow Transplant 12:155, 1993.PubMedGoogle Scholar
  121. 121.
    McGlave PB, DeFabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D: Autologous marrow transplant therapy for chronic myelogenous leukemia prolongs survival: Results from eight transplant groups. Lancet 343:1486, 1994.PubMedGoogle Scholar
  122. 122.
    Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringden O, Stone JAV, Bortin MM: Identical twin bone marrow transplants for leukemia. Ann Intern Med 120:646, 1994.PubMedGoogle Scholar
  123. 123.
    Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O’Reilly RJ, Keever CA: Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250, 1990.PubMedGoogle Scholar
  124. 124.
    Mackinnon S, Hows JM, Goldman JM: Induction of in-vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 76:2037, 1990.PubMedGoogle Scholar
  125. 125.
    Verma UN, Bagg A, Brown E, Mazumder A: Interleukin-2 activation of human bone marrow in long-term cultures — an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 13:115, 1994.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Reginald A. Clift

There are no affiliations available

Personalised recommendations